SI1951296T2 - Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom - Google Patents

Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom

Info

Publication number
SI1951296T2
SI1951296T2 SI200630957T SI200630957T SI1951296T2 SI 1951296 T2 SI1951296 T2 SI 1951296T2 SI 200630957 T SI200630957 T SI 200630957T SI 200630957 T SI200630957 T SI 200630957T SI 1951296 T2 SI1951296 T2 SI 1951296T2
Authority
SI
Slovenia
Prior art keywords
cell
dna
cell culture
betapropiolactone
low levels
Prior art date
Application number
SI200630957T
Other languages
English (en)
Slovenian (sl)
Other versions
SI1951296T1 (sl
Inventor
Jens-Peter Gregersen
Holger Kost
Original Assignee
Novartis Vaccines And Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1951296(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines And Diagnostics Gmbh filed Critical Novartis Vaccines And Diagnostics Gmbh
Publication of SI1951296T1 publication Critical patent/SI1951296T1/sl
Publication of SI1951296T2 publication Critical patent/SI1951296T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200630957T 2005-11-01 2006-11-01 Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom SI1951296T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01
PCT/IB2006/003880 WO2007052163A2 (en) 2005-11-01 2006-11-01 Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
EP06831855.9A EP1951296B2 (en) 2005-11-01 2006-11-01 Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment

Publications (2)

Publication Number Publication Date
SI1951296T1 SI1951296T1 (sl) 2011-04-29
SI1951296T2 true SI1951296T2 (sl) 2014-09-30

Family

ID=37969762

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630957T SI1951296T2 (sl) 2005-11-01 2006-11-01 Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom

Country Status (19)

Country Link
US (2) US10655108B2 (enExample)
EP (3) EP2301572B1 (enExample)
JP (5) JP5602366B2 (enExample)
KR (1) KR20080081254A (enExample)
CN (2) CN104474543A (enExample)
AT (1) ATE494906T1 (enExample)
AU (2) AU2006310171B2 (enExample)
CA (1) CA2627971A1 (enExample)
CY (1) CY1111378T1 (enExample)
DE (1) DE602006019629D1 (enExample)
DK (1) DK1951296T4 (enExample)
EA (1) EA014062B1 (enExample)
ES (2) ES2359214T5 (enExample)
HK (1) HK1207828A1 (enExample)
NZ (1) NZ567817A (enExample)
PL (2) PL2301572T3 (enExample)
PT (1) PT2301572E (enExample)
SI (1) SI1951296T2 (enExample)
WO (1) WO2007052163A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5602366B2 (ja) * 2005-11-01 2014-10-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン
AU2007209019B2 (en) 2006-01-27 2012-11-29 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
PT2185191E (pt) * 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP3459563B1 (en) 2008-03-18 2025-12-17 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
JP2012507272A (ja) * 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
HRP20121048T1 (hr) 2009-05-21 2013-02-28 Novartis Ag Reverzna genetika korištenjem ne-endogenih pol i promotora
WO2011012999A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
EP2485764A4 (en) 2009-10-09 2014-01-29 Childrens Medical Center SELECTIVELY DISCONNECTED FULL CELL VACCINE
EA023811B1 (ru) 2009-10-20 2016-07-29 Новартис Аг Способ получения вируса с использованием конструкции, кодирующей вирусную рнк
WO2011138229A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
JP6072677B2 (ja) 2010-05-06 2017-02-01 ノバルティス アーゲー 微生物の不活化のための有機ペルオキシド化合物
EP2571520B1 (en) 2010-05-21 2018-04-04 Seqirus UK Limited Influenza virus reassortment method
DK2575872T3 (da) 2010-06-01 2020-10-19 Seqirus Uk Ltd Koncentrering af influenzavaccineantigener uden frysetørring
BR112012030616A2 (pt) 2010-06-01 2017-03-01 Novartis Ag concentração de antígenos de vacina com liofilização.
US8778653B2 (en) 2010-08-12 2014-07-15 Yisheng Biopharma Holdings Ltd. Method for reducing DNA impurities in viral compositions
EP2605792B1 (en) 2010-08-20 2014-12-10 Novartis AG Soluble needle arrays for delivery of influenza vaccines
EP2678452B1 (en) * 2011-02-25 2016-02-24 Novartis AG Exogenous internal positive control for virus detection
KR102002103B1 (ko) 2011-11-03 2019-07-19 센티넥스트 테라퓨틱스 에쓰디엔 비에이취디 인간 엔테로바이러스에 대한 백신
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
AU2013205478B9 (en) 2012-03-02 2014-11-20 Seqirus UK Limited Influenza virus reassortment
EP2822585B1 (en) 2012-03-06 2017-05-17 Janssen Vaccines & Prevention B.V. Improved vaccination against influenza
WO2013182498A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
EP2925356A2 (en) 2012-12-03 2015-10-07 Novartis AG Reassortant influenza a viren
AU2014229255B2 (en) 2013-03-13 2018-12-13 Novartis Ag Influenza B virus reassortment
BR112015028314A2 (pt) 2013-05-10 2017-09-19 Steinman Lawrence Prevenção do risco de narcolepsia em vacinas para gripe
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
CA2914604A1 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CN104513317B (zh) * 2013-09-30 2018-12-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
KR20160068972A (ko) * 2013-11-15 2016-06-15 노파르티스 아게 잔여 세포 배양 불순물의 제거
WO2015179979A1 (en) * 2014-05-28 2015-12-03 National Health Research Institutes Viral particles as immunogens against enterovirus infection and production thereof
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017005880A1 (en) 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
CN114929270A (zh) * 2019-11-07 2022-08-19 塞其里斯英国有限公司 用于生产具有减小的颗粒大小的病毒疫苗的组合物和方法
AU2020389047A1 (en) 2019-11-18 2022-06-02 Seqirus Pty Ltd. Method for producing reassortant influenza viruses
KR20230157397A (ko) * 2021-03-30 2023-11-16 덴카 주식회사 인플루엔자 백신
CN115354071A (zh) * 2022-08-10 2022-11-18 上海药明生基医药科技有限公司 一种检测重组腺相关病毒宿主细胞dna残留的方法
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用
TW202516000A (zh) * 2023-07-25 2025-04-16 日商Ｋｍ生物醫藥股份有限公司 利用雞蛋培養法進行的去活化流感疫苗的製備方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CH589453A5 (enExample) * 1974-01-14 1977-07-15 Sandoz Ag
US4140762A (en) * 1974-01-14 1979-02-20 Sandoz Ltd. Influenza sub-unit vaccine
DE3788902T3 (de) 1986-06-17 2004-11-25 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung.
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
JP2941859B2 (ja) 1989-09-20 1999-08-30 国立予防衛生研究所 Ｈａ蛋白の製造法
US5010112A (en) * 1989-12-01 1991-04-23 Massachusetts Institute Of Technology Method and apparatus for improving the insulating properties of closed cell foam
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
ES2235489T3 (es) * 1998-06-01 2005-07-01 Chiron Corporation Uso de polimeros de acido hialuronico para la administracion por las mucosas de antigenos y coadyuvantes de vacunas.
JP2000230931A (ja) 1998-12-07 2000-08-22 Katakura Industries Co Ltd 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット
JP2002542203A (ja) * 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
PL355287A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
CA2393469A1 (en) 1999-12-08 2001-06-14 Crucell Holland B.V. Method of administering adenovirus
AU3604201A (en) 2000-03-03 2001-09-12 Chemo Sero Therapeut Res Inst Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
JP2004536785A (ja) 2001-02-23 2004-12-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
EP1361890B1 (en) * 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
AU2002254558A1 (en) 2001-04-27 2002-11-11 Becton, Dickinson And Company Novel vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
CN103540613A (zh) 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
AU2003299244A1 (en) 2002-12-20 2004-07-14 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
CA2522379C (en) * 2003-04-10 2012-10-23 Chiron Corporation The severe acute respiratory syndrome coronavirus
JP5215561B2 (ja) 2003-05-28 2013-06-19 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン及び遺伝子治療のための高力価組換えインフルエンザ・ウイルス
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
CA2555412C (en) 2004-02-23 2013-06-25 Crucell Holland B.V. Virus purification methods
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
CN101094915A (zh) 2004-05-20 2007-12-26 益得生物医学公司 生产流感疫苗的方法
PL2578229T3 (pl) * 2004-09-09 2014-01-31 Novartis Ag Zmniejszenie potencjalnego zagrożenia jatrogennego związanego z antygenami w szczepionce
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
CN103555670B (zh) 2004-12-23 2015-08-12 米迪缪尼有限公司 用于病毒增殖的非致瘤性mdck细胞系
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
JP5602366B2 (ja) * 2005-11-01 2014-10-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン
CA2663522C (en) * 2006-09-15 2015-06-02 Medimmune, Llc Mdck cell lines supporting viral growth to high titers and bioreactor process using the same

Also Published As

Publication number Publication date
JP2014198726A (ja) 2014-10-23
AU2011201968A1 (en) 2011-05-19
DE602006019629D1 (de) 2011-02-24
AU2006310171A1 (en) 2007-05-10
CA2627971A1 (en) 2007-05-10
CY1111378T1 (el) 2015-08-05
EP1951296A2 (en) 2008-08-06
PL1951296T5 (pl) 2015-06-30
WO2007052163A2 (en) 2007-05-10
CN101365480B (zh) 2014-11-05
EA014062B1 (ru) 2010-08-30
JP5602366B2 (ja) 2014-10-08
CN101365480A (zh) 2009-02-11
JP6639077B2 (ja) 2020-02-05
US20090304729A1 (en) 2009-12-10
AU2006310171B2 (en) 2011-02-17
PL2301572T3 (pl) 2015-02-27
NZ567817A (en) 2012-01-12
US10655108B2 (en) 2020-05-19
ES2525518T3 (es) 2014-12-26
JP7049761B2 (ja) 2022-04-07
JP2020023557A (ja) 2020-02-13
JP2011256209A (ja) 2011-12-22
CN104474543A (zh) 2015-04-01
BRPI0618094A2 (pt) 2011-08-16
EP1951296B1 (en) 2011-01-12
AU2011201968B2 (en) 2014-08-28
EP2842572A1 (en) 2015-03-04
JP2016185988A (ja) 2016-10-27
EA200801221A1 (ru) 2008-10-30
ES2359214T3 (es) 2011-05-19
PL1951296T3 (pl) 2011-09-30
EP2301572A1 (en) 2011-03-30
BRPI0618094A8 (pt) 2017-08-22
US20200377864A1 (en) 2020-12-03
WO2007052163A3 (en) 2007-09-07
DK1951296T4 (da) 2014-09-01
EP2301572B1 (en) 2014-09-10
US11466257B2 (en) 2022-10-11
HK1207828A1 (en) 2016-02-12
DK1951296T3 (da) 2011-03-28
SI1951296T1 (sl) 2011-04-29
JP2009513694A (ja) 2009-04-02
ATE494906T1 (de) 2011-01-15
EP1951296B2 (en) 2014-07-23
ES2359214T5 (es) 2014-10-08
HK1129837A1 (en) 2009-12-11
PT2301572E (pt) 2014-12-22
KR20080081254A (ko) 2008-09-09

Similar Documents

Publication Publication Date Title
SI1951296T2 (sl) Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2007024941A3 (en) Polyvalent vaccine
BR112013011194A2 (pt) partículas de glicoproteína semelhantes a vírus (vlps) da raiva.
WO2010019262A3 (en) Polyvalent vaccine
MX2012000035A (es) Antigenos de virus de sincicio respiratorio recombinantes.
PH12013502621A1 (en) Vaccine composition comprising an inactivated chikungunya virus strain
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2009026465A3 (en) Composition and methods of making and using influenza proteins
WO2010001409A3 (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2007117303A3 (en) Combination vaccine comprising an attenuated bovine viral diarrhea virus
EA201170533A1 (ru) Высокодиспергируемый диоксид кремния для резин и способ его получения
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
WO2008115314A3 (en) Flavivirus vaccine vector against influenza virus
MX2010006984A (es) Vacunas contra la malaria.
WO2007082734A3 (en) Influenza vaccine
PL1796717T3 (pl) Szczepionka skojarzona
MX348934B (es) Secuencias de aminoacidos para el control de patogenos.
TW200531701A (en) Method of vaccination against testicular BVDV infection